Omnicell, Inc. $OMCL Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. cut its position in Omnicell, Inc. (NASDAQ:OMCL) by 80.0% in the 1st quarter, Holdings Channel.com reports. The firm owned 51,728 shares of the company’s stock after selling 206,503 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Omnicell were worth $1,727,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Dana Investment Advisors Inc. bought a new stake in shares of Omnicell in the 4th quarter worth about $3,445,000. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Omnicell by 71.1% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 140,032 shares of the company’s stock valued at $6,343,000 after buying an additional 58,193 shares during the last quarter. Peregrine Capital Management LLC acquired a new stake in Omnicell during the fourth quarter valued at approximately $4,804,000. Dynamic Technology Lab Private Ltd lifted its holdings in Omnicell by 345.9% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 31,890 shares of the company’s stock worth $971,000 after buying an additional 24,738 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its holdings in Omnicell by 96.3% during the 4th quarter. Teachers Retirement System of The State of Kentucky now owns 25,914 shares of the company’s stock worth $1,174,000 after buying an additional 12,713 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Omnicell news, EVP Nnamdi Njoku sold 3,090 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $43.22, for a total value of $133,549.80. Following the completion of the sale, the executive vice president directly owned 154,785 shares of the company’s stock, valued at $6,689,807.70. The trade was a 1.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Corey J. Manley sold 5,025 shares of the company’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the completion of the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. This represents a 4.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Corporate insiders own 2.92% of the company’s stock.

Omnicell Trading Up 1.0%

Shares of NASDAQ OMCL opened at $41.93 on Thursday. Omnicell, Inc. has a one year low of $26.84 and a one year high of $55.00. The firm has a market capitalization of $1.91 billion, a PE ratio of 95.30, a PEG ratio of 1.07 and a beta of 0.96. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The business has a 50-day moving average price of $41.48 and a two-hundred day moving average price of $41.52.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.22. The company had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The firm’s quarterly revenue was up 14.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.26 EPS. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, analysts predict that Omnicell, Inc. will post 1.31 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of recent research reports. KeyCorp raised their target price on shares of Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Weiss Ratings raised Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. UBS Group set a $60.00 price objective on shares of Omnicell and gave the company a “buy” rating in a research note on Friday, March 13th. Benchmark reaffirmed a “buy” rating on shares of Omnicell in a report on Friday, March 13th. Finally, Wells Fargo & Company raised their price objective on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of “Buy” and a consensus price target of $59.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.